New Delhi: The Delhi High Court has granted an ex-parte ad-interim injunction in favour of Sun Pharmaceutical Medicare, a subsidiary of Sun Pharmaceutical Industries, restraining Alenvision Pharma and its associate company from manufacturing or marketing their migraine drug under the mark NEXADOM, which the court found deceptively similar to Sun Pharma's registered trademark NAXDOM.

The order was passed by Justice Manmeet Pritam Singh Arora on August 28, 2025, in a commercial suit filed by Sun Pharmaceutical Medicare seeking permanent injunction, damages, and appointment of a Local Commissioner to seize infringing stock.

Sun Pharmaceutical Medicare, a subsidiary of Sun Pharmaceutical Industries Ltd., argued that it coined the trademark NAXDOM in 2005, started using it in 2006, and obtai

See Full Page